I Kong1, S A Narod2, C Taylor3, L Paszat4, R Saskin3, S Nofech-Moses5, D Thiruchelvam3, W Hanna5, J P Pignol1, S Sengupta6, L Elavathil7, P A Jani8, S J Done9, S Metcalfe10, E Rakovitch11. 1. Department of Radiation Oncology, Women's College Research Institute, Toronto, ON. ; Sunnybrook Health Sciences Centre, Toronto, ON. ; University of Toronto, Toronto, ON. 2. University of Toronto, Toronto, ON. ; Women's College Research Institute, Toronto, ON. 3. Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON. 4. Department of Radiation Oncology, Women's College Research Institute, Toronto, ON. ; Sunnybrook Health Sciences Centre, Toronto, ON. ; University of Toronto, Toronto, ON. ; Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON. 5. University of Toronto, Toronto, ON. ; Department of Pathology, University of Toronto, Toronto, ON. 6. Department of Pathology, University of Toronto, Toronto, ON. ; Kingston General Hospital, Kingston, ON. 7. Department of Pathology, University of Toronto, Toronto, ON. ; Henderson General Hospital, Hamilton, ON. 8. Department of Pathology, University of Toronto, Toronto, ON. ; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON. 9. Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON. 10. Sunnybrook Health Sciences Centre, Toronto, ON. 11. Department of Radiation Oncology, Women's College Research Institute, Toronto, ON. ; Sunnybrook Health Sciences Centre, Toronto, ON. ; Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON. ; University of Toronto, Toronto, ON.
Abstract
PURPOSE: The main goal of treating ductal carcinoma in situ (dcis) is to prevent the development of invasive breast cancer. Most women are treated with breast-conserving surgery (bcs) and radiotherapy. Age at diagnosis may be a risk factor for recurrence, leading to concerns that additional treatment may be necessary for younger women. We report a population-based study of women with dcis treated with bcs and radiotherapy and an evaluation of the effect of age on local recurrence (lr). METHODS: All women diagnosed with dcis in Ontario from 1994 to 2003 were identified. Treatments and outcomes were collected through administrative databases and validated by chart review. Women treated with bcs and radiotherapy were included. Survival analyses were performed to evaluate the effect of age on outcomes. RESULTS: We identified 5752 cases of dcis; 1607 women received bcs and radiotherapy. The median follow-up was 10.0 years. The 10-year cumulative lr rate was 27% for women younger than 45 years, 14% for women 45-50 years, and 11% for women more than 50 years of age (p < 0.0001). The 10-year cumulative invasive lr rate was 22% for women younger than 45 years, 10% for women 45-50 years, and 7% for women more than 50 years of age (p < 0.0001). On multivariate analyses, young age (<45 years) was significantly associated with lr and invasive lr [hazard ratio (hr) for lr: 2.6; 95% confidence interval (ci): 1.9 to 3.7; p < 0.0001; hr for invasive lr: 3.0; 95% ci: 2.0 to 4.4; p < 0.0001]. An age of 45-50 years was also significantly associated with invasive lr (hr: 1.6; 95% ci: 1.0 to 2.4; p = 0.04). CONCLUSIONS: Age at diagnosis is a strong predictor of lr in women with dcis after treatment with bcs and radiotherapy.
PURPOSE: The main goal of treating ductal carcinoma in situ (dcis) is to prevent the development of invasive breast cancer. Most women are treated with breast-conserving surgery (bcs) and radiotherapy. Age at diagnosis may be a risk factor for recurrence, leading to concerns that additional treatment may be necessary for younger women. We report a population-based study of women with dcis treated with bcs and radiotherapy and an evaluation of the effect of age on local recurrence (lr). METHODS: All women diagnosed with dcis in Ontario from 1994 to 2003 were identified. Treatments and outcomes were collected through administrative databases and validated by chart review. Women treated with bcs and radiotherapy were included. Survival analyses were performed to evaluate the effect of age on outcomes. RESULTS: We identified 5752 cases of dcis; 1607 women received bcs and radiotherapy. The median follow-up was 10.0 years. The 10-year cumulative lr rate was 27% for women younger than 45 years, 14% for women 45-50 years, and 11% for women more than 50 years of age (p < 0.0001). The 10-year cumulative invasive lr rate was 22% for women younger than 45 years, 10% for women 45-50 years, and 7% for women more than 50 years of age (p < 0.0001). On multivariate analyses, young age (<45 years) was significantly associated with lr and invasive lr [hazard ratio (hr) for lr: 2.6; 95% confidence interval (ci): 1.9 to 3.7; p < 0.0001; hr for invasive lr: 3.0; 95% ci: 2.0 to 4.4; p < 0.0001]. An age of 45-50 years was also significantly associated with invasive lr (hr: 1.6; 95% ci: 1.0 to 2.4; p = 0.04). CONCLUSIONS: Age at diagnosis is a strong predictor of lr in women with dcis after treatment with bcs and radiotherapy.
Entities:
Keywords:
Ductal carcinoma in situ; age; radiation; recurrence; young patients
Authors: Laura A Lee; Melvin J Silverstein; Cathie T Chung; Heather Macdonald; Premal Sanghavi; Melinda Epstein; Dennis R Holmes; Howard Silberman; Wei Ye; Michael D Lagios Journal: Am J Surg Date: 2006-10 Impact factor: 2.565
Authors: B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Aurelius Omlin; Maurizio Amichetti; David Azria; Bernard F Cole; Philippe Fourneret; Philip Poortmans; Diana Naehrig; Robert C Miller; Marco Krengli; Cristina Gutierrez Miguelez; David Morgan; Hadassah Goldberg; Luciano Scandolaro; Pauline Gastelblum; Mahmut Ozsahin; Dagmar Dohr; David Christie; Ulrich Oppitz; Ufuk Abacioglu; Guenther Gruber Journal: Lancet Oncol Date: 2006-08 Impact factor: 41.316
Authors: Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark Journal: J Natl Cancer Inst Date: 2011-03-11 Impact factor: 13.506
Authors: Eileen Rakovitch; Steven A Narod; Sharon Nofech-Moses; Wedad Hanna; Deva Thiruchelvam; Refik Saskin; Carole Taylor; Alan Tuck; Bruce Youngson; Naomi Miller; Susan J Done; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Michel Bonin; Stephanie Metcalfe; Lawrence Paszat Journal: Int J Radiat Oncol Biol Phys Date: 2013-07-01 Impact factor: 7.038
Authors: Carlos Chavez de Paz Villanueva; Valentina Bonev; Maheswari Senthil; Naveenraj Solomon; Mark E Reeves; Carlos A Garberoglio; Jukes P Namm; Sharon S Lum Journal: JAMA Surg Date: 2017-11-01 Impact factor: 14.766
Authors: Megan E Tesch; Shoshana M Rosenberg; Laura C Collins; Julia S Wong; Laura Dominici; Kathryn J Ruddy; Rulla Tamimi; Lidia Schapira; Virginia F Borges; Ellen Warner; Steven E Come; Ann H Partridge Journal: Ann Surg Oncol Date: 2022-08-12 Impact factor: 4.339
Authors: M Luke Marinovich; Lamiae Azizi; Petra Macaskill; Les Irwig; Monica Morrow; Lawrence J Solin; Nehmat Houssami Journal: Ann Surg Oncol Date: 2016-08-15 Impact factor: 5.344
Authors: Janice S Sung; Sarah Stamler; Jennifer Brooks; Jennifer Kaplan; Tammy Huang; D David Dershaw; Carol H Lee; Elizabeth A Morris; Christopher E Comstock Journal: Radiology Date: 2016-04-20 Impact factor: 11.105